BMS-986226
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BMS-986226, covering 2023-02-28 to 2023-02-28. Get the full timeline:
Most recent: Clinical Trial Update: A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]